A PYMNTS Company

Republicans Question FTC’s Efforts To Halt Illumina’s Grail Deal

By  |  September 2, 2021

Two Republican lawmakers on Thursday questioned the Federal Trade Commission’s (FTC) efforts to unwind life science company Illumina’s US$7.1 billion acquisition of Grail, alleging the regulator was not following a normal path in its work, reported Reuters.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Members of Congress Jim Jordan and Darrell Issa wrote in a letter to FTC Chair Lina Khan that agency actions related to the deal require congressional oversight, demanding documents related to the FTC’s work.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    “The FTC’s approach to the Illumina-GRAIL merger departs from its typical enforcement process and raises questions about the Commission’s interference in the case,” the September 2 letter stated.

    Among their complaints, the members of Congress alleged that the FTC filed for an injunction in federal court to give it time to litigate the case before the FTC’s own internal administrative court “to avoid speedily resolving novel legal issues under U.S. law in a forum – federal district court – where the FTC was more likely to lose.”

    The FTC has argued that cancer test detection company Grail and its competitors rely on San Diego, California-based Illumina’s DNA sequencing technology. They alleged that Illumina’s purchase of Grail would give the company the “incentive and ability to foreclose downstream rivals.”

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.